Results 211 to 220 of about 2,266,569 (385)
T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma
Nature Medicine, 2022 Alexander X. Lozano, A. Chaudhuri, Aishwarya Nene, Antonietta Bacchiocchi, N. Earland, M. Vesely, A. Usmani, Brandon E Turner, C. Steen, Bogdan Luca, Ti Badri, G. Gulati, M. R. Vahid, Farnaz Khameneh, P. Harris, David Y. Chen, K. Dhodapkar, M. Sznol, R. Halaban, Aaron M. Newman +19 moresemanticscholar +1 more sourceInteractions of Antibody Drug Conjugate Anti‐Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy
Advanced Science, EarlyView.Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.Jacqueline Lesperance, Bryan S. Yung, Michael M. Allevato, Marcus M Cheng, Maria F. Camargo, Robert Saddawi‐Konefka, Kanika Dhawan, Ashwyn K. Sharma, Mahsa Mortaja, Sophie Bice, Daniel J. Scanderbeg, Diego Alvarado, Jyoti Mayadev, Ramez N. Eskander, Stephen R. Adams, Pippa F. Cosper, J. Silvio Gutkind, Sunil J. Advani +17 morewiley +1 more sourceBufalin Inhibits the PI3K/AKT Pathway by Targeting GTF3C4 to Impede Breast Cancer Progression
Advanced Science, EarlyView.Mechanisms of Bufalin‐Mediated Intervention in Breast Cancer. ABSTRACT
Breast cancer incidence is rising globally, presenting challenges such as treatment side effects and drug resistance. Bufalin is a bufadienolides compound with potential anti‐cancer effects. This study shows that bufalin inhibits malignant proliferation of MDA‐MB‐231 and MCF‐7 cells Siyu Guo, Xiaodong Chen, Haojia Wang, Jiying Zhou, Peiying Lu, Jiangying Liu, Keyan Chai, Jingyuan Zhang, Siyun Yang, Shan Lu, Yifei Gao, Zhengsen Jin, Xiaoyu Tao, Zhongdong Hu, Qinglin Li, Jiarui Wu +15 morewiley +1 more sourceAdditional file 1: of Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
, 2019 Jeffrey M. Conroy, Sarabjot Pabla, Mary Nesline, Sean T. Glenn, Antonios Papanicolau‐Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo, Yirong Wang, Felicia L. Lenzo, Wiam Bshara, Maya Khalil, Grace K. Dy, Katherine Madden, Keisuke Shirai, Konstantin H. Dragnev, Laura J. Tafe, Jason Zhu, Matthew Labriola, Daniele Marin, Shannon J. McCall, Jeffrey Clarke, Daniel J. George, Tian Zhang, Matthew R. Zibelman, Pooja Ghatalia, Isabel Araujo-Fernandez, Luis de la Cruz‐Merino, Arun K. Singavi, Ben George, Alexander C. Mackinnon, Jonathan R. Thompson, Rajbir Singh, Robin Jacob, Deepa Kasuganti, Neel Shah, Roger Day, Lorenzo Galluzzi, Mark Gardner, Carl Morrison +39 moreopenalex +1 more sourceYKT6 Promotes Bladder Cancer Progression by Stabilizing β‐catenin Through USP7‐Mediated Deubiquitination
Advanced Science, EarlyView.The SNARE protein YKT6 is upregulated in bladder cancer (BLCA), correlating with poor prognosis. YKT6 promotes tumor proliferation and metastasis by activating Wnt/β‐catenin signaling. It recruits Ubiquitin‐Specific Peptidase 7 (USP7) to deubiquitinate and stabilize β‐catenin, enhancing its nuclear accumulation and driving oncogenic gene expression ...Sheng Tu, Wenzhi Du, Yongwen Luo, Jiageng Shi, Tianyun Liu, Meng Ji, Kangping Xiong, Siming Chen, Fenfang Zhou, Mingxing Li, Jingtian Yu, Gang Wang, Lingao Ju, Yi Zhang, Yu Xiao, Xinghuan Wang, Kaiyu Qian +16 morewiley +1 more sourceFigure S2 from Subsets of interferon signaling predict response to immune checkpoint blockade in melanoma patients
Brooke Horowitch, Daniel Y. Lee, Min Ding, Sandra Martínez-Morilla, Thazin Nwe Aung, Feriel Ouerghi, Xueting Wang, Wei Wei, William Damsky, Mario Sznol, Harriet M. Kluger, David L. Rimm, Jeffrey J. Ishizuka +12 moreopenalex +1 more sourceSupplementary Table S1 from Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious <i>CDK12</i> Alterations in the Phase 2 IMPACT Trial [PDF]
Charles B. Nguyen, Melissa A. Reimers, Chamila Perera, Wassim Abida, Jonathan Chou, Felix Y. Feng, Emmanuel S. Antonarakis, Rana R. McKay, Russell K. Pachynski, Jingsong Zhang, Zachery R. Reichert, Phillip L. Palmbos, Megan E.V. Caram, Ulka N. Vaishampayan, Elisabeth I. Heath, Alexander C. Hopkins, Marcin Cieślik, Yi‐Mi Wu, Dan R. Robinson, Veerabhadran Baladandayuthapani, Arul M. Chinnaiyan, Ajjai Alva +21 moreopenalex +1 more source
